Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Peter D. Burbelo is active.

Publication


Featured researches published by Peter D. Burbelo.


Cell | 1996

Rac and Cdc42 induce actin polymerization and G1 cell cycle progression independently of p65PAK and the JNK/SAPK MAP kinase cascade.

Nathalie Lamarche; Nicolas Tapon; Lisa Stowers; Peter D. Burbelo; Pontus Aspenström; Tina Bridges; John Chant; Alan Hall

Rac and Cdc42 regulate a variety of responses in mammalian cells including formation of lamellipodia and filopodia, activation of the JNK MAP kinase cascade, and induction of G1 cell cycle progression. Rac is also one of the downstream targets required for Ras-induced malignant transformation. Rac and Cdc42 containing a Y40C effector site substitution no longer intact with the Ser/Thr kinase p65PAK and are unable to activate the JNK MAP kinase pathway. However, they still induce cytoskeletal changes and G1 cell cycle progression. Rac containing an F37A effector site substitution, on the other hand, no longer interacts with the Ser/Thr kinase p160ROCK and is unable to induce lamellipodia or G1 progression. We conclude that Rac and Cdc42 control MAP kinase pathways and actin cytoskeleton organization independently through distinct downstream targets.


The New England Journal of Medicine | 2012

Adult-onset immunodeficiency in Thailand and Taiwan

Sarah K. Browne; Peter D. Burbelo; Ploenchan Chetchotisakd; Yupin Suputtamongkol; Sasisopin Kiertiburanakul; Pamela A. Shaw; Jennifer L. Kirk; Kamonwan Jutivorakool; Rifat Zaman; Li Ding; Amy P. Hsu; Smita Y. Patel; Kenneth N. Olivier; Viraphong Lulitanond; Piroon Mootsikapun; Siriluck Anunnatsiri; Nasikarn Angkasekwinai; Boonmee Sathapatayavongs; Po-Ren Hsueh; Chi Chang Shieh; Margaret R. Brown; Wanna Thongnoppakhun; Reginald J. Claypool; Elizabeth P. Sampaio; Charin Thepthai; Duangdao Waywa; Camilla Dacombe; Yona Reizes; Adrian M. Zelazny; Paul Saleeb

BACKGROUND Autoantibodies against interferon-γ are associated with severe disseminated opportunistic infection, but their importance and prevalence are unknown. METHODS We enrolled 203 persons from sites in Thailand and Taiwan in five groups: 52 patients with disseminated, rapidly or slowly growing, nontuberculous mycobacterial infection (group 1); 45 patients with another opportunistic infection, with or without nontuberculous mycobacterial infection (group 2); 9 patients with disseminated tuberculosis (group 3); 49 patients with pulmonary tuberculosis (group 4); and 48 healthy controls (group 5). Clinical histories were recorded, and blood specimens were obtained. RESULTS Patients in groups 1 and 2 had CD4+ T-lymphocyte counts that were similar to those in patients in groups 4 and 5, and they were not infected with the human immunodeficiency virus (HIV). Washed cells obtained from patients in groups 1 and 2 had intact cytokine production and a response to cytokine stimulation. In contrast, plasma obtained from these patients inhibited the activity of interferon-γ in normal cells. High-titer anti-interferon-γ autoantibodies were detected in 81% of patients in group 1, 96% of patients in group 2, 11% of patients in group 3, 2% of patients in group 4, and 2% of controls (group 5). Forty other anticytokine autoantibodies were assayed. One patient with cryptococcal meningitis had autoantibodies only against granulocyte-macrophage colony-stimulating factor. No other anticytokine autoantibodies or genetic defects correlated with infections. There was no familial clustering. CONCLUSIONS Neutralizing anti-interferon-γ autoantibodies were detected in 88% of Asian adults with multiple opportunistic infections and were associated with an adult-onset immunodeficiency akin to that of advanced HIV infection. (Funded by the National Institute of Allergy and Infectious Diseases and the National Institute of Dental and Craniofacial Research; ClinicalTrials.gov number, NCT00814827.).


Mbio | 2014

Middle East Respiratory Syndrome Coronavirus Infection in Dromedary Camels in Saudi Arabia

Abdulaziz N. Alagaili; Thomas Briese; Nischay Mishra; Vishal Kapoor; Stephen Sameroff; Peter D. Burbelo; E. de Wit; Vincent J. Munster; Lisa E. Hensley; Iyad S. Zalmout; Amit Kapoor; Jonathan H. Epstein; William B. Karesh; Peter Daszak; Osama B. Mohammed; W. I. Lipkin

ABSTRACT The Middle East respiratory syndrome (MERS) is proposed to be a zoonotic disease; however, the reservoir and mechanism for transmission of the causative agent, the MERS coronavirus, are unknown. Dromedary camels have been implicated through reports that some victims have been exposed to camels, camels in areas where the disease has emerged have antibodies to the virus, and viral sequences have been recovered from camels in association with outbreaks of the disease among humans. Nonetheless, whether camels mediate transmission to humans is unresolved. Here we provide evidence from a geographic and temporal survey of camels in the Kingdom of Saudi Arabia that MERS coronaviruses have been circulating in camels since at least 1992, are distributed countrywide, and can be phylogenetically classified into clades that correlate with outbreaks of the disease among humans. We found no evidence of infection in domestic sheep or domestic goats. IMPORTANCE This study was undertaken to determine the historical and current prevalence of Middle East respiratory syndrome (MERS) coronavirus infection in dromedary camels and other livestock in the Kingdom of Saudi Arabia, where the index case and the majority of cases of MERS have been reported. This study was undertaken to determine the historical and current prevalence of Middle East respiratory syndrome (MERS) coronavirus infection in dromedary camels and other livestock in the Kingdom of Saudi Arabia, where the index case and the majority of cases of MERS have been reported.


Mbio | 2013

Identification of Rodent Homologs of Hepatitis C Virus and Pegiviruses

Amit Kapoor; Peter Simmonds; Troels K. H. Scheel; Brian Hjelle; John M. Cullen; Peter D. Burbelo; Lokendra V. Chauhan; Raja Duraisamy; Maria Sanchez Leon; Komal Jain; Kurt J. Vandegrift; Charles H. Calisher; Charles M. Rice; W. Ian Lipkin

ABSTRACT Hepatitis C virus (HCV) and human pegivirus (HPgV or GB virus C) are globally distributed and infect 2 to 5% of the human population. The lack of tractable-animal models for these viruses, in particular for HCV, has hampered the study of infection, transmission, virulence, immunity, and pathogenesis. To address this challenge, we searched for homologous viruses in small mammals, including wild rodents. Here we report the discovery of several new hepaciviruses (HCV-like viruses) and pegiviruses (GB virus-like viruses) that infect wild rodents. Complete genome sequences were acquired for a rodent hepacivirus (RHV) found in Peromyscus maniculatus and a rodent pegivirus (RPgV) found in Neotoma albigula. Unique genomic features and phylogenetic analyses confirmed that these RHV and RPgV variants represent several novel virus species in the Hepacivirus and Pegivirus genera within the family Flaviviridae. The genetic diversity of the rodent hepaciviruses exceeded that observed for hepaciviruses infecting either humans or non-primates, leading to new insights into the origin, evolution, and host range of hepaciviruses. The presence of genes, encoded proteins, and translation elements homologous to those found in human hepaciviruses and pegiviruses suggests the potential for the development of new animal systems with which to model HCV pathogenesis, vaccine design, and treatment. IMPORTANCE The genetic and biological characterization of animal homologs of human viruses provides insights into the origins of human infections and enhances our ability to study their pathogenesis and explore preventive and therapeutic interventions. Horses are the only reported host of nonprimate homologs of hepatitis C virus (HCV). Here, we report the discovery of HCV-like viruses in wild rodents. The majority of HCV-like viruses were found in deer mice (Peromyscus maniculatus), a small rodent used in laboratories to study viruses, including hantaviruses. We also identified pegiviruses in rodents that are distinct from the pegiviruses found in primates, bats, and horses. These novel viruses may enable the development of small-animal models for HCV, the most common infectious cause of liver failure and hepatocellular carcinoma after hepatitis B virus, and help to explore the health relevance of the highly prevalent human pegiviruses. The genetic and biological characterization of animal homologs of human viruses provides insights into the origins of human infections and enhances our ability to study their pathogenesis and explore preventive and therapeutic interventions. Horses are the only reported host of nonprimate homologs of hepatitis C virus (HCV). Here, we report the discovery of HCV-like viruses in wild rodents. The majority of HCV-like viruses were found in deer mice (Peromyscus maniculatus), a small rodent used in laboratories to study viruses, including hantaviruses. We also identified pegiviruses in rodents that are distinct from the pegiviruses found in primates, bats, and horses. These novel viruses may enable the development of small-animal models for HCV, the most common infectious cause of liver failure and hepatocellular carcinoma after hepatitis B virus, and help to explore the health relevance of the highly prevalent human pegiviruses.


Journal of Virology | 2012

Serology-Enabled Discovery of Genetically Diverse Hepaciviruses in a New Host

Peter D. Burbelo; Edward J. Dubovi; Peter Simmonds; J.L. Medina; Jose A. Henriquez; Nischay Mishra; J. Wagner; Rafal Tokarz; John M. Cullen; M.J. Iadarola; Charles M. Rice; W. I. Lipkin; Amit Kapoor

ABSTRACT Genetic and biological characterization of new hepaciviruses infecting animals contributes to our understanding of the ultimate origins of hepatitis C virus (HCV) infection in humans and dramatically enhances our ability to study its pathogenesis using tractable animal models. Animal homologs of HCV include a recently discovered canine hepacivirus (CHV) and GB virus B (GBV-B), both viruses with largely undetermined natural host ranges. Here we used a versatile serology-based approach to determine the natural host of the only known nonprimate hepacivirus (NPHV), CHV, which is also the closest phylogenetic relative of HCV. Recombinant protein expressed from the helicase domain of CHV NS3 was used as antigen in the luciferase immunoprecipitation system (LIPS) assay to screen several nonprimate animal species. Thirty-six samples from 103 horses were immunoreactive, and viral genomic RNA was present in 8 of the 36 seropositive animals and none of the seronegative animals. Complete genome sequences of these 8 genetically diverse NPHVs showed 14% (range, 6.4% to 17.2%) nucleotide sequence divergence, with most changes occurring at synonymous sites. RNA secondary structure prediction of the 383-base 5′ untranslated region of NPHV was refined and extended through mapping of polymorphic sites to unpaired regions or (semi)covariant pairings. Similar approaches were adopted to delineate extensive RNA secondary structures in the coding region of the genome, predicted to form 27 regularly spaced, thermodynamically stable stem-loops. Together, these findings suggest a promising new nonprimate animal model and provide a database that will aid creation of functional NPHV cDNA clones and other novel tools for hepacivirus studies.


FEBS Letters | 2002

Human RhoGAP domain‐containing proteins: structure, function and evolutionary relationships

Jeremy W. Peck; Gilbert Douglas; Catherine H Wu; Peter D. Burbelo

Proteins containing a RhoGAP (Rho TPase ctivating rotein) domain usually function to catalyze the hydrolysis of GTP that is bound to Rho, Rac and/or Cdc42, inactivating these regulators of the actin cytoskeleton. Using database searches, at least 53 distinct RhoGAP domain‐containing proteins are likely to be encoded in human DNA. Phylogenetic analysis of only the RhoGAP domains divides these proteins into distinct families that appear to be functionally related. We also review the current understanding of the structure and likely functions of these human proteins. The presence of RhoGAP domains in a number of different human proteins suggests that cytoskeletal changes, regulated by Rho GTPase, may be integrated with many different signaling pathways.


Blood | 2011

Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States

Jeffrey I. Cohen; Elaine S. Jaffe; Janet K. Dale; Stefania Pittaluga; Helen E. Heslop; Cliona M. Rooney; Stephen Gottschalk; Catherine M. Bollard; V. Koneti Rao; Adrianna Marques; Peter D. Burbelo; Siu-Ping Turk; Rachael Fulton; Alan S. Wayne; Richard F. Little; Mitchell S. Cairo; Nader Kim El-Mallawany; Daniel H. Fowler; Claude Sportes; Michael R. Bishop; Wyndham H. Wilson; Stephen E. Straus

Chronic active EBV disease (CAEBV) is a lymphoproliferative disorder characterized by markedly elevated levels of antibody to EBV or EBV DNA in the blood and EBV RNA or protein in lymphocytes in tissues. We present our experience with CAEBV during the last 28 years, including the first 8 cases treated with hematopoietic stem cell transplantation in the United States. Most cases of CAEBV have been reported from Japan. Unlike CAEBV in Japan, where EBV is nearly always found in T or natural killer (NK) cells in tissues, EBV was usually detected in B cells in tissues from our patients. Most patients presented with lymphadenopathy and splenomegaly; fever, hepatitis, and pancytopenia were common. Most patients died of infection or progressive lymphoproliferation. Unlike cases reported from Japan, our patients often showed a progressive loss of B cells and hypogammaglobulinemia. Although patients with CAEBV from Japan have normal or increased numbers of NK cells, many of our patients had reduced NK-cell numbers. Although immunosuppressive agents, rituximab, autologous cytotoxic T cells, or cytotoxic chemotherapy often resulted in short-term remissions, they were not curative. Hematopoietic stem cell transplantation was often curative for CAEBV, even in patients with active lymphoproliferative disease that was unresponsive to chemotherapy. These studies are registered at http://www.clinicaltrials.gov as NCT00032513 for CAEBV, NCT00062868 and NCT00058812 for EBV-specific T-cell studies, and NCT00578539 for the hematopoietic stem cell transplantation protocol.


The Journal of Infectious Diseases | 2008

A Luciferase Immunoprecipitation Systems Assay Enhances the Sensitivity and Specificity of Diagnosis of Strongyloides stercoralis Infection

Roshan Ramanathan; Peter D. Burbelo; Sandra Groot; Michael J. Iadarola; Franklin A. Neva; Thomas B. Nutman

BACKGROUND We investigated whether luciferase immunoprecipitation systems (LIPS) can be the basis for a more rapid, specific, and standardized assay for the diagnosis of Strongyloides stercoralis infection. METHODS A LIPS assay was developed based on immunoglobulin (Ig) G or IgG4 antibody to a recombinant Strongyloides antigen (NIE) and was compared with an NIE enzyme-linked immunosorbent assay (ELISA). A second antigen, S. stercoralis immunoreactive antigen (SsIR), was tested alone and in combination with NIE. The assays were tested using serum samples from patients with parasitologically proven S. stercoralis or filarial infections and from healthy, uninfected control subjects. RESULTS The NIE LIPS assay based on IgG antibody easily differentiated between S. stercoralis-infected and uninfected patients (P< .0001) and demonstrated improved specificity compared with the NIE ELISA (100% vs. 95%). Serum from filaria-infected patients did not cross-react when tested with the NIE LIPS assay. When SsIR was used in combination with NIE in the LIPS format, sensitivity and specificity improved to 100%, with a 7-fold difference between positive and negative values. No advantage was found in using a LIPS assay based on IgG4. At posttreatment follow-up, a significant decline in antibody titers was detected using the NIE ELISA (P< .0017) and the NIE LIPS assay (P< .0001). CONCLUSIONS LIPS addresses several limitations of current ELISAs and represents a major advance in the diagnosis of S. stercoralis infection.


Proceedings of the National Academy of Sciences of the United States of America | 2012

Early responses to adenoviral-mediated transfer of the aquaporin-1 cDNA for radiation-induced salivary hypofunction

Bruce J. Baum; Ilias Alevizos; Changyu Zheng; Ana P. Cotrim; Shuying Liu; Linda McCullagh; Corinne M. Goldsmith; Peter D. Burbelo; Deborah Citrin; James B. Mitchell; Liesl Nottingham; Susan F. Rudy; Carter Van Waes; Millie Whatley; Jaime S. Brahim; John A. Chiorini; Stamatina Danielides; R. James Turner; Nicholas J. Patronas; Clara C. Chen; Nikolay Nikolov; Gabor G. Illei

No conventional therapy exists for salivary hypofunction in surviving head and neck cancer patients with Radiation Therapy Oncology Group late grade 2–3 toxicity. We conducted a phase I clinical trial to test the safety and biologic efficacy of serotype 5, adenoviral-mediated aquaporin-1 cDNA transfer to a single previously irradiated parotid gland in 11 subjects using an open label, single-dose, dose-escalation design (AdhAQP1 vector; four dose tiers from 4.8 × 107 to 5.8 × 109 vector particles per gland). Treated subjects were followed at scheduled intervals. Multiple safety parameters were measured and biologic efficacy was evaluated with measurements of parotid salivary flow rate. Symptoms were assessed with a visual analog scale. All subjects tolerated vector delivery and study procedures well over the 42-d study period reported. No deaths, serious adverse events, or dose-limiting toxicities occurred. Generally, few adverse events occurred, and all were considered mild or moderate. No consistent changes were found in any clinical chemistry and hematology parameters measured. Objective responses were seen in six subjects, all at doses <5.8 × 109 vector particles per gland. Five of these six subjects also experienced subjective improvement in xerostomia. AdhAQP1 vector delivery to a single parotid gland was safe and transfer of the hAQP1 cDNA increased parotid flow and relieved symptoms in a subset of subjects.


Blood | 2010

Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia

Peter D. Burbelo; Sarah K. Browne; Elizabeth P. Sampaio; Giuseppe Giaccone; Rifat Zaman; Ervand Kristosturyan; Arun Rajan; Li Ding; Kathryn H. Ching; Arlene Berman; Joao Bosco Oliveira; Amy P. Hsu; Caitlin M. Klimavicz; Michael J. Iadarola; Steven M. Holland

Patients with thymic malignancy have high rates of autoimmunity leading to a variety of autoimmune diseases, most commonly myasthenia gravis caused by anti-acetylcholine receptor autoantibodies. High rates of autoantibodies to cytokines have also been described, although prevalence, spectrum, and functionality of these anti-cytokine autoantibodies are poorly defined. To better understand the presence and function of anti-cytokine autoantibodies, we created a luciferase immunoprecipitation system panel to search for autoantibodies against 39 different cytokines and examined plasma from controls (n = 30) and patients with thymic neoplasia (n = 17). In this screen, our patients showed statistically elevated, but highly heterogeneous immunoreactivity against 16 of the 39 cytokines. Some patients showed autoantibodies to multiple cytokines. Functional testing proved that autoantibodies directed against interferon-α, interferon-β, interleukin-1α (IL-1α), IL-12p35, IL-12p40, and IL-17A had biologic blocking activity in vitro. All patients with opportunistic infection showed multiple anti-cytokine autoantibodies (range 3-11), suggesting that anti-cytokine autoantibodies may be important in the pathogenesis of opportunistic infections in patients with thymic malignancy. This study was registered at http://clinicaltrials.gov as NCT00001355.

Collaboration


Dive into the Peter D. Burbelo's collaboration.

Top Co-Authors

Avatar

Michael J. Iadarola

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Kathryn H. Ching

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Jeffrey I. Cohen

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Yoshihiko Yamada

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Ahmad Bayat

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Joseph A. Kovacs

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Thomas B. Nutman

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Ilias Alevizos

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Dana M. Pirone

Georgetown University Medical Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge